Analyst consensus rating
Grace Therapeutics Analyst Rating: Strong Buy
Direct answer
Grace Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.85.
Forecast evidence checked November 13, 2026.
Get free Grace Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.81
- Average price target
- $5.85
- High price target
- $7.81
- Low price target
- $3.89
- Low target gap
- +114.9%
- Target upside
- +223.1%
- High target gap
- +331.3%
- Target range width
- 216.4%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Grace Therapeutics?
Grace Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $5.85.
How far are Grace Therapeutics's low and high targets from the recorded price?
The low target implies +114.9%, while the high target implies +331.3%.
How many analysts are included in Grace Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Grace Therapeutics's target upside or downside calculated?
The average target of $5.85 is divided by the recorded price of $1.81, then one is subtracted to produce +223.1%. This does not guarantee a future return.
When was Grace Therapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.